Amy Jensen-Smith
Amy Jensen-Smith earned her B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst, and completed her Ph.D. in Physiology at Dartmouth College. She continued her scientific training as a Postdoctoral Fellow at the National Cancer Institute and as a Presidential Postdoctoral Fellow at Novartis Institutes for BioMedical Research (NIBR).
Amy began her industry career at bluebird bio, where she led multidisciplinary teams focused on the development of CAR and TCR T cell therapies, managed strategic partnerships, and helped advance several preclinical programs. She played a key role in expanding tumor biology expertise and driving innovation in gene editing and cell therapy.
In 2020, Amy joined SOTIO as Senior Director and later became Vice President, Head of Discovery. She built and led the Discovery team, advancing programs based on SOTIO’s BOXR technology and contributing to multiple clinical candidate selections and patent filings. She also helped define the company’s strategic focus on ADCs and oversaw the progression of antibody-drug conjugate programs from concept to candidate selection. In 2025, Amy was appointed Chief Scientific Officer.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
